Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (IKT): 4 pipeline candidates · 3 upcoming catalysts · ~41 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
41.0 months
D/E 0.03 · 31% dilution
Lead: Phase 3
4 candidates
3 upcoming, next in ~1262d
N/A
A transparent, data-derived signal for Inhibikase Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$220.5M
Cash
$49.6M
Quarterly Burn
$12.1M
Runway
41.0 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ikt-001 | Phase 3 |
| ikt-001pro | Phase 3 |
| imatinib | Phase 1 |
| risvodetinib | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$130.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 8,901,330 | $15.0M |
| adar1 capital management, llc | 6,606,572 | $11.1M |
| kalehua capital management llc | 6,494,498 | $10.9M |
| blackrock, inc. | 6,303,433 | $10.6M |
| blackstone inc. | 5,938,276 | $10.0M |
| commodore capital lp | 5,397,488 | $9.1M |
| perceptive advisors llc | 4,630,000 | $7.8M |
| saturn v capital management lp | 3,863,445 | $6.5M |
| spruce street capital lp | 3,581,603 | $6.0M |
| squadron capital management llc | 3,500,000 | $5.9M |
Showing top 10 of 99 institutional holders of Inhibikase Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Inhibikase Therapeutics, Inc.'s pipeline?
Inhibikase Therapeutics, Inc. (IKT) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inhibikase Therapeutics, Inc.'s lead drug candidate?
Inhibikase Therapeutics, Inc.'s most advanced tracked candidate is ikt-001 (Phase 3) for Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension (PAH).
What is Inhibikase Therapeutics, Inc.'s next catalyst?
Inhibikase Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and" — expected December 1, 2029.
What is Inhibikase Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Inhibikase Therapeutics, Inc. has approximately 41.0 months of cash runway.
What is Inhibikase Therapeutics, Inc.'s market capitalization?
Inhibikase Therapeutics, Inc.'s market capitalization is approximately $220.5M.
Get the full picture on Inhibikase Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.